论文部分内容阅读
目的:探讨可溶性Endoglin水平检测对乳腺癌患者的临床价值。方法:收集55例健康女性、123例乳腺癌患者以及其中84例乳腺癌患者手术前后血清,采用酶联免疫吸附试验(ELISA)检测可溶性Endoglin水平。结果:乳腺癌患者及健康女性的可溶性Endoglin水平分别为(5.07±1.23)、(3.27±0.47)pg/mL,两者有统计学差异(P=0.00,t=10.76);乳腺癌患者临床Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为(4.23±0.26)、(4.85±0.34)、(5.37±0.37)、(6.21±0.51)pg/mL,两两比较差异均有统计学意义(P<0.01或P<0.05);Ⅳ期乳腺癌患者明显高于其他各期(P=0.00,t=9.63)。Endoglin水平随临床分期升高而上升。Endoglin水平在不同年龄层无统计学差异(P=0.589,t=0.314)。Endoglin水平在不同病理类型间无统计学差异(P=0.483,t=0.254)。84例手术患者Endoglin水平手术前后有统计学差异(P=0.00,t=9.35)。结论:乳腺癌患者可溶性Endoglin水平在不同分期、不同病理类型间以及手术前后有变化,对于判断病情与评估预后有一定的参考意义。
Objective: To investigate the clinical value of detecting soluble Endoglin in patients with breast cancer. Methods: The serum levels of 55 healthy women, 123 breast cancer patients and 84 breast cancer patients before and after surgery were collected. The levels of soluble Endoglin were detected by enzyme - linked immunosorbent assay (ELISA). Results: The levels of soluble Endoglin in breast cancer patients and healthy women were (5.07 ± 1.23) and (3.27 ± 0.47) pg / mL respectively, with statistical significance (P = 0.00, t = 10.76) (4.23 ± 0.26), (4.85 ± 0.34), (5.37 ± 0.37) and (6.21 ± 0.51) pg / mL in group Ⅱ, Ⅲ and Ⅳ, respectively P <0.05). The stage IV breast cancer patients were significantly higher than those in other stages (P = 0.00, t = 9.63). Endoglin levels rise with clinical stage. There was no significant difference in endoglin levels between different ages (P = 0.589, t = 0.314). There was no significant difference in Endoglin levels between different pathological types (P = 0.483, t = 0.254). 84 cases of surgical patients with Endoglin levels before and after surgery were statistically significant (P = 0.00, t = 9.35). Conclusion: The level of soluble endoglin in patients with breast cancer varies in different stages, different pathological types and before and after surgery, which is of certain reference value for judging the condition and evaluating the prognosis.